[go: up one dir, main page]

ES2058272T3 - Fluoxetina util para el tratamiento de la diabetes. - Google Patents

Fluoxetina util para el tratamiento de la diabetes.

Info

Publication number
ES2058272T3
ES2058272T3 ES88303930T ES88303930T ES2058272T3 ES 2058272 T3 ES2058272 T3 ES 2058272T3 ES 88303930 T ES88303930 T ES 88303930T ES 88303930 T ES88303930 T ES 88303930T ES 2058272 T3 ES2058272 T3 ES 2058272T3
Authority
ES
Spain
Prior art keywords
fluoxetine
diabetes
useful
treatment
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88303930T
Other languages
English (en)
Inventor
David Taiwai Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2058272T3 publication Critical patent/ES2058272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCION SE REFIERE AL EMPLEO DE FLUOXENTINA PARA CONTROLAR LA DIABETES EN MAMIFEROS.
ES88303930T 1987-05-04 1988-04-29 Fluoxetina util para el tratamiento de la diabetes. Expired - Lifetime ES2058272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4550987A 1987-05-04 1987-05-04

Publications (1)

Publication Number Publication Date
ES2058272T3 true ES2058272T3 (es) 1994-11-01

Family

ID=21938301

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88303930T Expired - Lifetime ES2058272T3 (es) 1987-05-04 1988-04-29 Fluoxetina util para el tratamiento de la diabetes.

Country Status (11)

Country Link
EP (1) EP0294028B1 (es)
JP (1) JP2721507B2 (es)
KR (1) KR880013555A (es)
AT (1) ATE93721T1 (es)
AU (1) AU596296B2 (es)
DE (1) DE3883606T2 (es)
DK (1) DK238588A (es)
ES (1) ES2058272T3 (es)
HK (1) HK19595A (es)
PH (1) PH23901A (es)
ZA (1) ZA883115B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2039103A1 (en) * 1990-03-29 1991-09-30 David Wayne Robertson Improvements in and relating to the selective occupation of serotonin 1c receptors
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
DE602004012403T2 (de) 2003-04-29 2009-03-19 Orexigen Therapeutics, Inc., La Jolla Zusammensetzungen zur beeinflussung des gewichtsverlusts
PL2135603T3 (pl) * 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2089005B1 (en) 2006-11-09 2010-03-17 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
TW200829235A (en) 2006-11-09 2008-07-16 Orexigen Therapeutics Inc Methods for administering weight loss medications
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
CA2875056C (en) 2012-06-06 2024-03-26 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EA201590047A1 (ru) 2012-07-31 2015-09-30 Сановел Хайван Саглиги Юрюнлери Санайи Ве Тиджарет А.С. Применение флуоксетина для увеличения мясной и молочной продуктивности
US20150190352A1 (en) 2012-07-31 2015-07-09 Sanovel Hayvan Sagligi Ürünleri Sanayi Ve Ticaret Anonim Sirketi Use of fluoxetine in animals
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4590213A (en) * 1983-04-08 1986-05-20 Eli Lilly And Company Anti-anxiety method
ZA861211B (en) * 1985-02-25 1987-10-28 Lilly Co Eli Analgesic composition

Also Published As

Publication number Publication date
AU596296B2 (en) 1990-04-26
JP2721507B2 (ja) 1998-03-04
EP0294028A3 (en) 1990-05-02
KR880013555A (ko) 1988-12-21
DK238588D0 (da) 1988-05-03
EP0294028B1 (en) 1993-09-01
AU1553388A (en) 1988-11-10
EP0294028A2 (en) 1988-12-07
JPS63284126A (ja) 1988-11-21
ZA883115B (en) 1990-01-31
ATE93721T1 (de) 1993-09-15
DK238588A (da) 1988-11-05
HK19595A (en) 1995-02-17
DE3883606D1 (de) 1993-10-07
PH23901A (en) 1989-12-18
DE3883606T2 (de) 1994-01-20

Similar Documents

Publication Publication Date Title
ES2058272T3 (es) Fluoxetina util para el tratamiento de la diabetes.
NO873243L (no) Legemiddel med antitumorvirkning.
DE3580069D1 (de) Mechanismus zum vorspannen von lagern.
ES533142A0 (es) Un procedimiento mejorado para la produccion de oxigeno de pureza 96% como minimo por destilacion criogenica y su correspondiente aparato mejorado.
ES2061587T3 (es) Compuestos aromaticos y heteroaromaticos alfa,alfa-disustituidos como mejoradores de la cognicion.
DE3875272D1 (de) Mit hydroxy-benzimidazoloxiden modifizierte kautschukmischungen.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
ES532696A0 (es) Procedimiento para el tratamiento de textiles
DE3854179D1 (de) Vulkanisierbare Fluorkautschukzusammensetzung.
ES2042726T3 (es) Beta-alquilmelatoninas.
ES2021122B3 (es) Proceso de cromocurtimiento altamente consuntivo.
ES2018807B3 (es) Procedimiento para curtir el cuero
ES553272A0 (es) Procedimiento para el tratamiento del material carnalitico
DE3885846D1 (de) Kontrollierte Stromquelle.
ES2019583B3 (es) Composicion para el tratamiento de infecciones.
ES549320A0 (es) Procedimiento para el analisis de la hemoglobina
DE3688742D1 (de) 2,2-diphenoxy-n,n-dimethylaminoaethan zur verbesserung der sauerstoffversorgung des gehirns.
ES533277A0 (es) Mejoras introducidas en el objeto de la patente principal n 516.338 por mejoras en cardas
ES1002501Y (es) Hucha perfeccionada para el ahorro aumentativo por niveles
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.
DE3877947D1 (de) Kautschukzusammensetzung.
ES544408A0 (es) Mejoras introducidas en el objeto de la patente principal n.534.390, por: sistema para el autoencendido de cigarrillos.
ES1003998Y (es) Dispositivo perfeccionado para el ensamble lateral de paneles.
ES529046A0 (es) Mejoras introducidas en el objeto de la patente principal n 513.469, por: procedimiento para preparar derivados de pirimidona
AR240397A1 (es) Banera para aplicacion de hidromasajes por burbujeo.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 294028

Country of ref document: ES